CPIX · Cumberland Pharmaceuticals Inc · Financials
Market Cap
$106.90M
Shares
14.98M
Volume · Oct 9
30.4K
Avg daily vol (3M)
87.14K
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Revenue
$44.52M
+17.6%
FY2025
Net Income
-$2.84M
+56.2%
FY2025
Gross Margin
85.02%
+2.4pp
FY2025
Operating Margin
-6.27%
+10.7pp
FY2025
Diluted EPS
-$0.19
+58.7%
FY2025
Operating Cash Flow
$4.93M
+905.7%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $31.27M | $44.52M | $37.87M | $39.55M | $42.01M | $35.99M | $37.44M | $34.39M | $29.34M | $41.15M | $33.03M | $900K | $600K | $800K | $700K | $51.14M | $45.88M | $43.54M | |
| $7.18M | $6.67M | $6.59M | $6.07M | $9.12M | $8.81M | $8.65M | $7.42M | $6.02M | $7.37M | $5.96M | $4.97M | $5.05M | $5.44M | $5.05M | $5.36M | $3.59M | $4.14M | |
| $24.31M | $37.85M | $31.28M | $33.49M | $32.89M | $27.17M | $28.79M | $26.97M | $23.33M | $33.78M | $27.07M | -$4.07M | -$4.45M | -$4.64M | -$4.35M | $45.78M | $42.29M | $39.4M | |
| — | 85.02% | 82.61% | 84.66% | 78.29% | 75.51% | 76.89% | 78.42% | 79.5% | 82.09% | 81.96% | -452.02% | -742.19% | -579.93% | -620.88% | 89.51% | 92.18% | 90.5% | |
| $5.66M | $5.57M | $4.82M | $5.83M | $6.69M | $5.68M | $5.77M | $6.87M | $7.58M | $4.28M | $3.19M | $3.85M | $3.39M | $5.62M | $5.1M | $5.03M | $4.33M | $4.99M | |
| $19.93M | $19.1M | $17.02M | $18.45M | $16.66M | $15.02M | $14.77M | $15.28M | $14M | $21.49M | $14.55M | $13.99M | $14.9M | $14.39M | $20.33M | $20.94M | $22.67M | $20.19M | |
| $11.93M | $11.95M | $11.13M | $10.65M | $10.18M | $9.78M | $10.2M | $9.97M | $10.15M | $9.65M | $8.56M | $7.61M | $8.4M | $9.49M | $9.06M | $9.31M | $8.1M | $7.64M | |
| $4.28M | $4.03M | $4.75M | $8.1M | $5.07M | $4.37M | $4.43M | $4.13M | $2.77M | $2.44M | $2.19M | $1.99M | $1.6M | $896.16K | $506.33K | $655.3K | $686.91K | $686.9K | |
| $4.14M | $4.15M | $4.9M | $4.94M | $5.33M | $4.61M | $4.75M | $4.4M | $2.98M | $2.65M | $2.4M | $2.25M | $1.99M | $1.3M | $901.65K | $1.04M | $978.4K | $816.5K | |
| $48.98M | $47.31M | $44.3M | $49.11M | $47.72M | $43.66M | $43.82M | $43.68M | $40.52M | $45.23M | $34.46M | $32.41M | $33.34M | $35.83M | $40.03M | $41.29M | $39.37M | $37.76M | |
| -$9.63M | -$2.79M | -$6.43M | -$9.55M | -$5.7M | -$7.68M | -$6.38M | -$9.29M | -$11.17M | -$4.08M | -$1.43M | $1.11M | $3.56M | -$3.8M | $8.82M | $9.85M | $6.5M | $5.78M | |
| — | -6.27% | -16.99% | -24.16% | -13.58% | -21.34% | -17.04% | -27.01% | -38.07% | -9.92% | -4.34% | 123.51% | 593.14% | -475.17% | 1259.73% | 19.26% | 14.17% | 13.27% | |
| -$5.49M | $1.35M | -$1.53M | -$4.62M | -$376.82K | -$3.07M | -$1.63M | -$4.88M | -$8.19M | -$1.43M | $963.78K | $3.36M | $5.55M | -$2.5M | $9.72M | $10.89M | $7.48M | $6.59M | |
| $418.28K | $495.99K | $605.51K | $667.86K | $586K | $98.03K | $263.63K | $246.19K | $195.85K | $92.9K | $106.39K | $73.86K | $67.07K | $103.42K | $71.99K | $353.5K | $1.42M | $772.93K | |
| $362.47K | $476.75K | $334.44K | $286.85K | $98.41K | $26.08K | $75.35K | $243.36K | $564.48K | $299.33K | $204.66K | $209.18K | $251.45K | $230.29K | $304.87K | $210.73K | $200.21K | $79.36K | |
| — | -$13.22K | $0 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | -$13.22K | $0 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| -$7.31M | -$2.81M | -$6.47M | -$6.28M | -$5.58M | -$5.56M | -$6.57M | -$9.29M | -$10.8M | -$3.87M | -$1.33M | $1.25M | $3.74M | -$3.67M | $9.05M | $9.71M | $5.28M | $5.08M | |
| $36.66K | $40.26K | -$22.67K | $45.77K | $68.85K | $34.89K | $55.9K | -$79.32K | $16.64K | $4.17M | -$330.92K | $575.83K | $1.38M | -$1.52M | $3.24M | $4.08M | $2.85M | $2.02M | |
| -$10.92M | -$2.84M | -$6.48M | -$6.28M | -$5.57M | -$3.51M | -$3.34M | -$3.54M | -$6.96M | -$7.98M | -$944.68K | $731.35K | $2.42M | -$2.1M | $5.84M | $5.66M | $2.46M | $3.09M | |
| — | -6.37% | -17.11% | -15.88% | -13.26% | -9.75% | -8.92% | -10.29% | -23.73% | -19.39% | -2.86% | 81.26% | 403.95% | -263.08% | 834.64% | 11.06% | 5.36% | 7.1% | |
| -$20.7K | -$28.58K | $36.06K | -$51.45K | -$79.8K | -$95.21K | -$79.5K | -$8752 | -$75.7K | -$71.18K | -$59.26K | -$60.24K | -$61.26K | -$46.8K | -$36.29K | -$31.34K | -$29.67K | -$32.54K | |
| -$4.57M | — | — | — | — | — | — | -$3.55M | -$7.04M | -$8.05M | -$1M | $671.11K | $2.36M | -$2.15M | $5.81M | $5.63M | $2.43M | — | |
| USD/shares | -$0.73 | -$0.19 | -$0.46 | -$0.44 | -$0.38 | -$0.24 | -$0.22 | -$0.23 | -$0.45 | -$0.50 | -$0.06 | $0.04 | $0.14 | -$0.11 | $0.30 | $0.28 | $0.12 | $0.22 |
| USD/shares | -$0.73 | -$0.19 | -$0.46 | -$0.44 | -$0.38 | -$0.24 | -$0.22 | -$0.23 | -$0.45 | -$0.50 | -$0.06 | $0.04 | $0.14 | -$0.11 | $0.30 | $0.28 | $0.12 | $0.17 |
| shares | — | 14.85M | 14.06M | 14.3M | 14.56M | 14.9M | 15.16M | 15.4M | 15.61M | 15.91M | 16.24M | 16.72M | 17.62M | 18.33M | 19.56M | 20.34M | 20.33M | 14.2M |
| shares | — | 14.85M | 14.06M | 14.3M | 14.56M | 14.9M | 15.16M | 15.4M | 15.61M | 15.91M | 16.24M | 17.09M | 17.9M | 18.33M | 19.79M | 20.57M | 21.06M | 18.23M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2009–FY2025: $77.43M in buybacks.
Debt Profile
Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Reported debt balances
Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.
| Reported balance | As of | Amount | Source |
|---|---|---|---|
| Noncurrent line of credit borrowings | 2026-06-30 | USD 0 | 10-Q filed 2026-08-07 |
| Operating lease liabilities | 2026-06-30 | USD 4,714,184 | 10-Q filed 2026-08-07 |
Related accounting measures — not additional borrowingCarrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year.
| |||
Instrument and agreement coverage is incomplete. Additional filings are awaiting review.
Covenants
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 1.11×
EV/EBIT
—
Peer median 7.50×
P/E (TTM)
—
Peer medians compare against the 47 similar-size Drug Manufacturers - Specialty & Generic companies (of 99 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Geography (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Non Us | $4,900,000 | $2,700,000 | $1,100,000 | $1,500,000 | $2,200,000 | $2,400,000 | $1,500,000 | $2,100,000 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Product | $40,396,278 | $36,537,704 | $37,513,492 | $40,681,182 | $35,045,259 | $35,840,673 | $32,407,845 | $28,803,961 |
| Product Sancuso | $11,907,141 | $9,005,129 | $8,096,788 | $13,205,603 | — | — | — | — |
| Product Kristalose | $10,542,793 | $15,315,259 | $15,981,850 | $15,205,155 | — | — | — | — |
| Product Vibativ | $9,484,874 | $7,160,125 | $8,812,692 | $7,487,462 | $11,704,062 | $10,870,990 | $8,691,550 | $5,075,057 |
| Product Caldolor | $4,659,457 | $4,959,385 | $4,333,923 | $4,827,200 | — | — | — | — |
| Product Other | $4,125,153 | $1,330,241 | — | — | — | — | — | — |
| Manufactured Product Other | $4,125,153 | $1,330,241 | $2,039,015 | $1,329,767 | $939,784 | $1,600,461 | $1,980,450 | $540,933 |
| Product Talicia | $3,311,235 | $0 | — | — | — | — | — | — |
| Product Acetadote | $508,169 | $185,182 | $458,759 | $501,040 | — | — | — | — |
| Product RediTrex | $11,391 | $90,237 | -$341,886 | -$126,726 | — | — | — | — |
| Product Omeclamox Pak | -$10,436 | -$3,075 | $20,030 | $29,145 | — | — | — | — |
| Product Vaprisol | -$18,346 | -$174,538 | $151,336 | -$447,697 | — | — | — | — |
| Acetadote | — | — | — | $501,040 | $850,993 | $1,874,206 | $3,824,449 | $4,284,111 |
| Caldolor | — | — | — | $4,827,200 | $4,970,301 | $5,336,943 | $5,222,282 | $5,001,997 |
| Kristalose | — | — | — | $15,205,155 | $15,993,658 | $15,567,562 | $12,895,120 | $12,055,625 |
| Omeclamox Pak | — | — | — | — | -$388,657 | $257,088 | $837,829 | $623,297 |
| Product Ethyol | — | — | — | — | — | — | $12,774,831 | $10,545,906 |
| Product Totect | — | — | — | — | — | — | $369,912 | $850,965 |
| RediTrex | — | — | — | -$126,726 | $55,321 | $856,657 | — | — |
| Sancuso | — | — | — | $13,205,603 | $0 | — | — | — |
| Vaprisol | — | — | — | -$447,697 | $1,859,581 | $1,077,227 | $936,615 | $1,763,874 |